Results 31 to 40 of about 131,254 (306)

Global Manufacturing of CAR T Cell Therapy

Molecular Therapy: Methods & Clinical Development, 2017
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types.
Bruce L. Levine, James Miskin, Keith Wonnacott, Christopher Keir   +3 more
doaj   +1 more source

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Frontiers in Immunology, 2018
Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for ...
Rohtesh S. Mehta, Katayoun Rezvani
doaj   +1 more source

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Journal of Medical Case Reports, 2022
Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu   +20 more
doaj   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source

Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular Cloning

, 2022
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular ...
Anthony J Bais (13285305)
core   +1 more source

Chimeric Antigen Receptor (CAR)-T Cell Therapy [PDF]

, 2018
Article信州医学雑誌 66(6): 425-433(2018)journal ...
齋藤, 章治, 中沢, 洋三
core   +1 more source

The pharmacology of second-generation chimeric antigen receptors [PDF]

Nature Reviews Drug Discovery, 2015
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation, metabolism and persistence of engineered T cells.
Sjoukje J C, van der Stegen, Mohamad, Hamieh, Michel, Sadelain   +2 more
openaire   +2 more sources

Gene-modified T-cell Therapy Using Chimeric Antigen Receptor [PDF]

, 2013
Article信州医学雑誌 61(4):197-203(2013)journal ...
中沢, 洋三
core   +1 more source

EXPRESSION OF A FUNCTIONAL CHIMERIC lg-MHC CLASS II PROTEIN [PDF]

, 1992
composed of the a- and ß-chains of the MHC class I1 I-E molecule fused to antibody V regions derived from anti-human CD4 mAb MT310. Expression vectors were constructed containing the functional, rearranged gene segments coding for the V region domains of
Zwirner, Jörg, Widera, Georg, Rieber, Ernst Peter, Karlsson, Lars, Peterson, Per A., Becker, Andrea, Weissenhorn, Winfried, Weiss, Elisabeth H., Riethmüller, Gert   +8 more
core   +1 more source

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues ...
Alejandro Ramírez-Chacón, Alejandro Ramírez-Chacón, Sergi Betriu-Méndez, Sergi Betriu-Méndez, Ariadna Bartoló-Ibars, Ariadna Bartoló-Ibars, Azucena González, Azucena González, Azucena González, Mercè Martí, Mercè Martí, Manel Juan, Manel Juan, Manel Juan   +13 more
doaj   +1 more source